Changing Scientific Times Drive NIGMS Research Agenda

SIDEBAR: High Risk, High Payoff From the early days of research in molecular biology--the discovery of restriction enzymes, which paved the way for recombinant technology, for example--to pharmacologist Alfred G. Gilman's 1994 Nobel Prize-winning investigations of G proteins, scientists funded by the National Institute of General Medical Sciences (NIGMS) have been advancing the life sciences. In fact, more than half of the National

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

SIDEBAR: High Risk, High Payoff

From the early days of research in molecular biology--the discovery of restriction enzymes, which paved the way for recombinant technology, for example--to pharmacologist Alfred G. Gilman's 1994 Nobel Prize-winning investigations of G proteins, scientists funded by the National Institute of General Medical Sciences (NIGMS) have been advancing the life sciences. In fact, more than half of the National Institutes of Health-supported Nobel Prize winners have received grants from NIGMS.

Today the institute--which supports extramural investigators almost exclusively--funds basic research in such areas as cell biology, genetics, and biochemistry aimed at finding out how systems work, usually before the implications for specific diseases are known.

Last October, NIGMS reorganized its administrative structure with the purpose, according to an institute statement, of becoming more efficient in its support of basic biomedical research and training and to reflect the increasingly interdisciplinary nature of science.

Specifically, four program branches--cellular ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Karen Kreeger

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours